Fevertree Drinks has seen its share price move in very different directions over different time frames, which puts a spotlight on whether the current valuation really lines up with the cash it can generate. With the stock now trading around £9.15, the key issue is how much of its future cash flow story is already embedded in that price.
-
Over the past 5 years the share price has fallen 59.0%, which raises a direct question about how the market is now weighing Fevertree Drinks' long term cash generation against earlier expectations.
-
The business relies heavily on turning premium mixer sales into steady free cash flow, so the strength and consistency of that cash conversion may support or limit how far the intrinsic value can stretch from here.
-
Prefer to judge Fevertree Drinks on earnings? See why Fevertree Drinks's 40.8x P/E tells a different valuation story .
The issue now is whether Fevertree Drinks' current share price can be justified by an intrinsic value estimate built on its cash flows.
If you want to stress test the same cash flow question you are asking of Fevertree Drinks across a broader opportunity set, take a look at 12 high quality undervalued stocks .
Is Fevertree Drinks a Bargain on Cash Flow?
The Discounted Cash Flow (DCF) model here focuses on the cash Fevertree Drinks can return to shareholders over time. Over the latest twelve months the group produced free cash flow of about £22.7 million, with analyst projections pointing to higher annual cash generation by the end of the next decade.
Those estimates imply a business that is expected to keep growing free cash flow from current levels rather than staying flat or shrinking, which matters when you compare that cash profile with a share price of £9.14. On these assumptions, the DCF projections put Fevertree Drinks' estimated intrinsic value substantially above the current share price. The key question for you is whether those future cash flow expectations feel realistic enough to support that gap. Find out what Fevertree Drinks could be worth using our Discounted Cash Flow (DCF) estimate .
The Fevertree Drinks Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where that valuation gap for Fevertree Drinks leaves off. They spell out which paths for growth, profit margins and earnings would need to play out for the stock to be worth materially more or less than today's price on the Community page. Each narrative links its number to a clear view on how growth, profitability and key risks might evolve, giving you a reference point you can revisit as new information comes through.
Fevertree Drinks splits opinion, with some community members seeing enough momentum and cash generation to back the current setup while others focus more on execution and category risks.
Bull case: roughly fairly valued
"The capital light outsourced model is already supporting strong cash conversion and £160m of share buybacks across 2025 and 2026 that reduce the share count by about 7%, which can amplify the effect of any future growth in EBITDA and free cash flow on earnings per share..."
Discover why this Narrative puts Fevertree Drinks at roughly fairly valued .
Bear case: 43% overvalued
"Bearish analysts expect rising health awareness, moderation trends and economic pressure on household budgets to keep weighing on premium mixer consumption, which may limit Fevertree Drinks' ability to expand volumes and sustain margins..."
Explore why this Narrative puts Fevertree Drinks at 43% overvalued .
Before acting on Fevertree Drinks' valuation, there is one more piece to check
Cash flows and scenarios only tell part of the story, because the people steering Fevertree Drinks and the way they are rewarded can either reinforce or undercut that whole investment case. See who runs Fevertree Drinks and how they are paid .
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include FEVR.aim .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
